CT-95 in Advanced Cancers Associated With Mesothelin Expression
← catalyst calendarNCT06756035 · readout ≤ 134 d
Sponsored by Context Therapeutics Inc. (industry) · CNTX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
70estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-31 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mesothelin-Expressing Tumors
- Epithelial Ovarian Cancer
- Malignant Pleural Mesothelioma, Advanced
- Malignant Peritoneal Mesothelioma, Advanced
- Pancreatic Adenocarcinoma Advanced or Metastatic
- Lung Adenocarcinoma Metastatic
- Cholangiocarcinoma Advanced
- Cholangiocarcinoma Non-resectable
- Mesothelin-expressing Advanced Cancers
- Mesothelin-positive Advanced Malignant Solid Tumors
- Colorectal Cancer
Intervention
- Drug: CT-95
Primary outcomes
what the primary-completion date above is the date OFDetermine the MTD or RD of CT-95 [Safety and Tolerability]
measured From date of first dose of CT-95 until 28 days following the first dose.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured From date of first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.
Permalink · CNTX's whole pipeline · Catalyst calendar · Every registered study · What changed